Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 24

Cited In for PubMed (Select 14695171)

1.

Sirt7 promotes gastric cancer growth and inhibits apoptosis by epigenetically inhibiting miR-34a.

Zhang S, Chen P, Huang Z, Hu X, Chen M, Hu S, Hu Y, Cai T.

Sci Rep. 2015 Apr 10;5:9787. doi: 10.1038/srep09787.

2.

Regulation of the DNA damage response by ubiquitin conjugation.

Brinkmann K, Schell M, Hoppe T, Kashkar H.

Front Genet. 2015 Mar 10;6:98. doi: 10.3389/fgene.2015.00098. eCollection 2015. Review.

3.

Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis.

Song P, Yin Q, Lu M, Fu BO, Wang B, Zhao Q.

Exp Ther Med. 2015 Apr;9(4):1393-1400. Epub 2015 Feb 11.

4.

Methylation-mediated gene silencing as biomarkers of gastric cancer: a review.

Nakamura J, Tanaka T, Kitajima Y, Noshiro H, Miyazaki K.

World J Gastroenterol. 2014 Sep 14;20(34):11991-2006. doi: 10.3748/wjg.v20.i34.11991. Review.

5.

Aberrant promoter methylation of caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC.

Brodie SA, Lombardo C, Li G, Kowalski J, Gandhi K, You S, Khuri FR, Marcus A, Vertino PM, Brandes JC.

PLoS One. 2014 Sep 15;9(9):e107124. doi: 10.1371/journal.pone.0107124. eCollection 2014.

6.

Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer.

Zhang YW, Zheng Y, Wang JZ, Lu XX, Wang Z, Chen LB, Guan XX, Tong JD.

Epigenetics. 2014 Jun;9(6):896-909. doi: 10.4161/epi.28601. Epub 2014 Apr 3.

7.

Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.

Derks S, Cleven AH, Melotte V, Smits KM, Brandes JC, Azad N, van Criekinge W, de Bruïne AP, Herman JG, van Engeland M.

Cancer Metastasis Rev. 2014 Mar;33(1):161-71. doi: 10.1007/s10555-013-9462-4. Review.

8.

CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.

Pelosof L, Yerram SR, Ahuja N, Delmas A, Danilova L, Herman JG, Azad NS.

Int J Cancer. 2014 Feb 1;134(3):596-605. doi: 10.1002/ijc.28390. Epub 2013 Aug 24.

9.

CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.

Pillai RN, Brodie SA, Sica GL, Shaojin Y, Li G, Nickleach DC, Yuan L, Varma VA, Bonta D, Herman JG, Brock MV, Ribeiro MJ, Ramalingam SS, Owonikoko TK, Khuri FR, Brandes JC.

Clin Cancer Res. 2013 Mar 15;19(6):1603-11. doi: 10.1158/1078-0432.CCR-12-2995. Epub 2013 Feb 5.

10.

Endometrial Cancer and Hypermethylation: Regulation of DNA and MicroRNA by Epigenetics.

Banno K, Kisu I, Yanokura M, Masuda K, Kobayashi Y, Ueki A, Tsuji K, Yamagami W, Nomura H, Susumu N, Aoki D.

Biochem Res Int. 2012;2012:738274. doi: 10.1155/2012/738274. Epub 2012 Apr 3.

11.

CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation.

Kashima L, Idogawa M, Mita H, Shitashige M, Yamada T, Ogi K, Suzuki H, Toyota M, Ariga H, Sasaki Y, Tokino T.

J Biol Chem. 2012 Apr 13;287(16):12975-84. doi: 10.1074/jbc.M111.321828. Epub 2012 Feb 15.

12.

The auto-ubiquitylation of E3 ubiquitin-protein ligase Chfr at G2 phase is required for accumulation of polo-like kinase 1 and mitotic entry in mammalian cells.

Kim JS, Park YY, Park SY, Cho H, Kang D, Cho H.

J Biol Chem. 2011 Sep 2;286(35):30615-23. doi: 10.1074/jbc.M111.231803. Epub 2011 Jul 15.

13.

RNF8-dependent histone ubiquitination during DNA damage response and spermatogenesis.

Ma T, Keller JA, Yu X.

Acta Biochim Biophys Sin (Shanghai). 2011 May;43(5):339-45. doi: 10.1093/abbs/gmr016. Epub 2011 Mar 28. Review.

14.

Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis.

Ding SZ, Goldberg JB, Hatakeyama M.

Future Oncol. 2010 May;6(5):851-62. doi: 10.2217/fon.10.37. Review.

15.

Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice.

Fu Z, Regan K, Zhang L, Muders MH, Thibodeau SN, French A, Wu Y, Kaufmann SH, Lingle WL, Chen J, Tindall DJ.

J Clin Invest. 2009 Sep;119(9):2714-24. doi: 10.1172/JCI37405. Epub 2009 Aug 17.

16.

Cancer DNA methylation: molecular mechanisms and clinical implications.

McCabe MT, Brandes JC, Vertino PM.

Clin Cancer Res. 2009 Jun 15;15(12):3927-37. doi: 10.1158/1078-0432.CCR-08-2784. Epub 2009 Jun 9.

17.

Checkpoint with forkhead-associated and ring finger promoter hypermethylation correlates with microsatellite instability in gastric cancer.

Oki E, Zhao Y, Yoshida R, Masuda T, Ando K, Sugiyama M, Tokunaga E, Morita M, Kakeji Y, Maehara Y.

World J Gastroenterol. 2009 May 28;15(20):2520-5.

18.

Enhanced genomic instabilities caused by deregulated microtubule dynamics and chromosome segregation: a perspective from genetic studies in mice.

Rao CV, Yamada HY, Yao Y, Dai W.

Carcinogenesis. 2009 Sep;30(9):1469-74. doi: 10.1093/carcin/bgp081. Epub 2009 Apr 16. Review.

19.

CHFR: A Novel Mitotic Checkpoint Protein and Regulator of Tumorigenesis.

Privette LM, Petty EM.

Transl Oncol. 2008 Jul;1(2):57-64.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk